Therefore, in this review, we discuss the beneficial sympatholytic effects that the novel drug class, sodium glucose co-transporter 2 (SGLT2) inhibitors have on hypertension in the MetS. The gene discussed is SLC5A2; the disease is metabolic syndrome.